## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

## IN THE CLAIMS:

Claims 1-3 (canceled).

Claim 4 (previously presented): A method for cultivating a skin material\_for grafting onto a neodermis of a human patient, comprising:

growing a first layer of human dermal fibroblasts upon a basal side of a biosynthetic substratum of an esterified hyaluronic acid;

growing a second human dermal fibroblast layer upon an upper side of said biosynthetic substratum; and

after said second dermal fibroblast layer begins to proliferate, growing a layer of keratinocytes over said second layer to form a composite skin material, said keratinocytes having been harvested from said patient.

Claim 5 (previously presented): The method according to claim 4 wherein said dermal fibroblasts are allogenic to the keratinocytes.

Claim 6 (previously presented): The method according to claim 4 wherein said dermal fibroblasts are autologous to the keratinocytes.

Claim 7 (canceled).

Claim 8 (previously presented): A skin material for grafting onto a neodermis of a human patient, said material comprising a composite of:

- a biosynthetic substratum of an esterified hyaluronic acid;
- a layer of viable human dermal fibroblasts upon an upper side of said biosynthetic substratum; and

a layer of viable human keratinocytes over said dermal fibroblasts upon said upper side of said substratum, said keratinocytes having been harvested from said patient.

Claim 9 (previously presented): The material according to claim 8 wherein said dermal fibroblasts are allogenic to the keratinocytes.

Claim 10 (previously presented): The material according to claim 8 wherein said dermal fibroblasts are autologous to the keratinocytes.

Claim 11 (previously presented): A skin material for grafting onto a neodermis of a human patient, said material comprising a composite of:

- a biosynthetic substratum of an esterified hyaluronic acid;
- a first layer of viable human dermal fibroblasts upon a basal side of said biosynthetic substratum;
- a second layer of viable human dermal fibroblasts upon an upper side of said biosynthetic substratum; and
- a layer of viable human keratinocytes over said dermal fibroblasts upon said upper side of said substratum, said keratinocytes having been harvested from said patient.

Claim 12 (previously presented): The material according to claim 11 wherein said dermal fibroblasts are allogenic to the keratinocytes.

Claim 13 (previously presented): The material according to claim 11 wherein said dermal fibroblasts are autologous to the keratinocytes.

Claim 14 (canceled).

Claim 15 (previously presented): A method for grafting a cultivated skin material onto a human patient, comprising the steps of:

applying an artificial skin substrate upon a wound bed of said patient; said artificial skin substrate comprising a layer of collagen-glycoaminoglycan on a basal side to be juxtaposed to said wound bed and a covering membrane of silicone on an opposing upper side;

allowing a vascularized wound bed to form under said collagen-glycoaminoglycan; thereupon

removing said silicone membrane; and

applying a basal side of a sheet of the cultivated skin material over said collagenglycoaminoglycan, said cultivated skin material comprising a layer of keratinocytes overlying a layer of viable human dermal fibroblasts upon an upper side of a biosynthetic substratum, said keratinocytes being harvested from said patient.

Claim 16 (canceled).

Claim 17 (previously presented): The method according to claim 15 wherein said cultivated skin material further comprises a layer of dermal fibroblasts upon said basal side of said biosynthetic substratum.

Claim 18 (previously presented): A method according to claim 15, wherein said biosynthetic substratum is a substratum of an esterified hyaluronic acid.

Claim 19 (canceled).

Claim 20 (previously presented): The method according to claim 18 wherein said cultivated skin material further comprises a layer of dermal fibroblasts upon said basal side of said biosynthetic substratum.

Claim 21 (canceled).

Claim 22 (previously presented): The method of claim 4, wherein the esterified hyaluronic acid is benzyl esterified hyaluronic acid.

Claim 23 (previously presented): The material of claim 8, wherein the substratum is a membrane comprising benzyl esterified hyaluronic acid.

Claim 24 (previously presented): The material of claim 11, wherein the substratum is a membrane comprising benzyl esterified hyaluronic acid.

Claim 25 (previously presented): The method of claim 18, wherein the substratum is a membrane comprising benzyl esterified hyaluronic acid.

Claim 26 (canceled).

Claim 27 (previously presented): The method of claim 22, wherein the membrane has holes capable of draining exudate.

Claim 28 (previously presented): The material of claim 23, wherein the membrane has holes capable of draining exudate.

Claim 29 (previously presented): The material of claim 24, wherein the membrane has holes capable of draining exudate.

Claim 30 (previously presented): The method of claim 25, wherein the membrane has holes capable of draining exudate.

Claim 31 (previously presented): A method for grafting a cultivated skin material onto the wound bed of a human patient, comprising the steps of:

covering the wound bed with a neodermis, and

applying the cultivated skin material onto the neodermis; said cultivated skin material comprising a basal side and an upper side of a biosynthetic substratum and a layer of keratinocytes overlying a layer of viable human dermal fibroblasts upon said upperside, said keratinocytes being harvested from said patient.

**PATENT** 

Appl. No. 09/365,677 Amdt. dated November 5, 2003 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1632

Claim 32 (previously presented): The method of claim 31, wherein said fibroblasts are autologous to the keratinocytes.

Claim 33 (previously presented): The method of claim 31, wherein said cultivated skin material further comprises a layer of dermal fibroblasts upon said basal side of said biosynthetic substratum.

## Amendment(s) to the Drawings:

Please amend the drawing sheets setting forth Figs. A1-A6 of Appendix A as indicated on the attached sheets.

The attached Replacement Sheets 3/5 -5/5 of the drawings relate to the renumbering of Figs. A1 to A6 respectively as Figs. 3-8:

The first sheet, Replacement Sheet 3/5, includes Figs. 3 and 4 replaces the original sheet including Figs. A1 and A2.

The second sheet, Replacement Sheet 4/5, includes Figs. 5 and 6 replaces the original sheet including Figs A3 and A4.

The third sheet, Replacement Sheet 5/5, includes Figs. 7 and 8 replaces the original sheet including Figures A5 and A6.

Attachment: Replacement Sheets 3/5, 4/5, 5/5 for drawings,

Annotated Sheets 3/5, 4/5, 5/5 Showing Changes of Replacement Sheets 3/5, 4/5, 5/5.